Daré Bioscience, Inc. (DARE) AI Stock Analysis
DARE AI stock analysis summary
AI ResearchDaré Bioscience, Inc. (DARE) is a clinical-stage biopharmaceutical company focused on developing therapies for women's healthcare, including its commercial product XACIATO. The company reported TTM revenue of $1.4M with an operating margin of -1582.5%. With a market cap of $14.3M, DARE carries net cash of $5.9M alongside negative shareholders' equity of -$560,100.
- Market cap
- $14.3M
- Revenue (TTM)
- $1.4M
- P/E
- — fwd 1.3x
- 1Y return
- -65.8% S&P 500 16.8%
- Avg. target
- $8.33 1049.4% vs last close
Bull case
- Wall Street analysts set an average price target of $8.33, representing 1049.4% upside to the last close of $0.72.
- Quarterly revenue grew 499.6% year-over-year in the period ending June 30, 2026.
- Dare Bioscience maintains a net cash reserve of $5.9M as of June 30, 2026.
Bear case
- Operating margin over the trailing twelve months was deep in negative territory at -1582.5%.
- Shareholders' equity sits at -$560,100 with a current ratio below parity at 0.99 as of June 30, 2026.
- DARE shares have dropped 65.8% over the past year and trade 55.9% below their 200-day moving average.
What Daré Bioscience does
Dare Bioscience, Inc. is a San Diego, California-based clinical-stage biopharmaceutical company dedicated to women's health. Its portfolio targets contraception, fertility, and sexual and vaginal health. The company's flagship commercial product is XACIATO, a single-dose vaginal gel approved for bacterial vaginosis in females aged 12 and older. Its advanced clinical pipeline features Ovaprene, a hormone-free monthly contraceptive, and Sildenafil Cream for female sexual arousal disorder. Dare is also advancing Phase 1-ready candidates including DARE-HRT1 for vasomotor symptoms and DARE-VVA1 for vulvar and vaginal atrophy, alongside pre-clinical programs DARE-LARC1 and DARE-RH1.
Growth and profitability
Dare Bioscience's top line has fluctuated substantially, moving from $10.0M in FY2021 and FY2022 down to $2.8M in FY2023 and $9,784 in FY2024. In FY2025, revenue recovered to $1.0M, representing 10429.4% growth, while operating margin was -1315.5% and net income stood at -$13.4M. For the latest quarter ended June 30, 2026, quarterly revenue growth reached 499.6% year-over-year, lifting trailing twelve-month revenue to $1.4M. TTM operating margin sits at -1582.5% and diluted earnings per share over the trailing twelve months is -$0.71.
Balance sheet and cash flow
As of June 30, 2026, Dare Bioscience held $12.6M in cash and short-term investments against $6.8M in total debt, yielding a net cash position of $5.9M. Total assets stood at $22.4M, with a current ratio of 0.99 and negative shareholders' equity of -$560,100. In FY2025, free cash flow was -$10.3M and capital expenditures totaled $385,278. Over five years, the company's share count expanded by 243.4%.
Valuation and performance
DARE trades at a price-to-sales ratio of 10.4x and an enterprise value to revenue multiple of 3.2x, compared to the median of its US-listed Healthcare peers of 4.1x price-to-sales. Its forward P/E is 1.3x versus the peer group median of 17.3x. Dare Bioscience's market cap is $14.3M, with an enterprise value of $4.3M. Over the past year, DARE fell 65.8%, underperforming the SPY return of 16.8%, and its 5-year return is -96.2% versus 83.0% for SPY.
What analysts expect
Wall Street coverage includes 2 Strong Buy ratings and 1 Buy rating. The mean price target is $8.33, representing a 1049.4% premium over the October 16, 2026 close of $0.72. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.77 on revenue of $2.7M. Dare Bioscience has beaten EPS estimates in each of the last 4 quarters, and its next earnings release is scheduled for November 12, 2026.
Key risks and what to watch
- Significant dilution risk exists, evidenced by a 243.4% increase in share count over 5 years.
- Free cash flow burn remained elevated at -$10.3M in FY2025 against $12.6M in cash and short-term investments.
- Negative equity of -$560,100 creates potential balance sheet and capital structure vulnerabilities.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this DARE AI stock analysis
This page is an AI-written research summary of Daré Bioscience, Inc. (DARE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: DARE income statement, DARE balance sheet, DARE key metrics, DARE analyst forecast, DARE chart. See the DARE stock overview for the latest quote and news.
DARE AI stock analysis FAQ
What products does Dare Bioscience commercialize?
Dare's flagship marketed product is XACIATO, an FDA-approved single-dose vaginal gel for bacterial vaginosis in females 12 and older.
What is DARE's net cash position?
As of June 30, 2026, Dare Bioscience held $12.6M in cash and short-term investments and $6.8M in total debt, leaving net cash of $5.9M.
What is the consensus analyst target for DARE?
The mean analyst price target is $8.33, which is 1049.4% higher than the October 16, 2026 closing price of $0.72.
When is Dare Bioscience's next earnings report?
The company's next earnings date is November 12, 2026.